Clinical Trial Update: Phase 2/3 Study of ALK-001 in Geographic Atrophy [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 study of ALK-001 in Geographic Atrophy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• ALK-001

Snippet

Sponsor: Alkeus Pharmaceuticals, Inc. | Conditions: Geographic Atrophy, Age Related Macular Degeneration | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-10-16